Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 3/20 | 1.00 |
| ▸ | CPT1B | Q92523 | 3/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 11/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960972 | 0.94 | CPT1A (0.88) | CPT1ACPT1BPTGER4KDM4CP2RY14 | |
| SCHEMBL962045 | 0.91 | CPT1A (0.83) | CPT1ACPT1BKDM4CP2RY14 | |
| SCHEMBL961693 | 0.91 | CPT1A (0.83) | CPT1ACPT1BKDM4CP2RY14 | |
| SCHEMBL962451 | 0.89 | CPT1A (0.80) | CPT1ACPT1BPTGER4KDM4C | |
| SCHEMBL958522 | 0.88 | CPT1A (0.78) | CPT1ACPT1BPTGER4 | |
| SCHEMBL960160 | 0.86 | CPT1A (0.75) | CPT1ACPT1BKDM4C | |
| SCHEMBL958061 | 0.85 | CPT1A (0.74) | CPT1ACPT1BPTGER4 | |
| SCHEMBL960379 | 0.84 | CPT1A (0.74) | CPT1ACPT1BPTGER4 | |
| SCHEMBL959454 | 0.83 | CPT1A (0.71) | CPT1ACPT1BKDM4C | |
| SCHEMBL958176 | 0.82 | CPT1A (0.70) | CPT1ACPT1BPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | claimed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | claimed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | claimed |
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | disclosed |
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885PTGER4 1048/4885 |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885PTGER4 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.